1.

[Article] Bloy, Cassie and Sarma, Ananya and Marsh, Bethan and Hardy, Lorna and Grabski, Meryem and Mollaahmetoglu, Merve and Shotton, Joshua and Bhaskaran, Shamhethan and Lingford-Hughes, Anne and Curran, H Val and Morgan, Celia and Lawn, Will (2026) The psychoactive effects of repeated ketamine infusions and their mechanistic role in the treatment of alcohol use disorder: Secondary analysis of a randomised controlled trial. Addiction, Early online. https://doi.org/10.1111/add.70320

2.

[Report] European Union Drugs Agency. (2026) Precursor assessment report of 4’-chloropropiophenone. Lisbon: EUDA.

3.

[Report] European Union Drugs Agency. (2026) Precursor assessment report of phenyl-2-nitropropene. Lisbon: EUDA.

4.

[Report] European Union Drugs Agency. (2026) Precursor assessment report of 2-bromo-3′-chloropropiophenone. Lisbon: EUDA.

5.

[Report] European Union Drugs Agency. (2026) Precursor assessment report of 2-bromo-3′-methylpropiophenone. Lisbon: EUDA.

6.

[Report] European Union Drugs Agency. (2026) Precursor assessment report of 2-bromo-4′-chloropropiophenone. Lisbon: EUDA.

7.

[Report] European Union Drugs Agency. (2026) Precursor assessment report of 2-bromo-4′-methylpropiophenone. Lisbon: EUDA.

8.

[Report] European Union Drugs Agency. (2026) Precursor assessment report of 3′-chloropropiophenone. Lisbon: EUDA.

9.

[Report] European Union Drugs Agency. (2026) Precursor assessment report of 3′-methylpropiophenone. Lisbon: EUDA.

10.

[Report] European Union Drugs Agency. (2026) Precursor assessment report of 4′-methylpropiophenone. Lisbon: EUDA.

11.

[Report] Advisory Council on the Misuse of Drugs. (2026) ACMD report – A review of the evidence on the use and harms of etomidate and related compounds. London: Advisory Council on the Misuse of Drugs.

12.

[Article] Chen, Shuoqi and Aldabergenov, Daniyar and Alotaibi, Khalid S and Holland, Adam and Moore, Robert and Woodhouse, Rebecca and Hudson, Simon and Milton, Holly and Menzies, Eleanor and Parks, Claire and Lawson, Alexander J and Harris, Magdalena and Singer, Mervyn and Dyson, Alex and Copeland, Caroline S (2026) Is nitazene-related mortality underestimated? Findings from an in vivo and ex vivo rat study and pharmacoepidemiological analysis of coroner-reported deaths. Clinical Toxicology, Early online. https://doi.org/10.1080/15563650.2025.2601141

13.

[News] European Union Drugs Agency. [EUDA] EU takes action to control three harmful new drugs. (30 Jan 2026)

14.

[Article] James, Philip D and Nash, Michael and Comiskey, Catherine and Prakashini Banka Cullen, Sonam (2026) Demographic and route to treatment differences between people using different substances in the Republic of Ireland: a comparative analysis using data from an EU wide treatment demand protocol. Journal of Drug Issues, Early online. https://doi.org/10.1177/00220426261419782

15.

[Article] Ledlie, Shaleesa and Garg, Ria and Leece, Pamela and Kolla, Gillian and Hyshka, Elaine and Tadrous, Mina and Gomes, Tara (2026) Trends in fentanyl-containing drug samples seized by law enforcement agencies across Canada. Addiction, Early online. https://doi.org/10.1111/add.70314

16.

[Article] Gworek, Hanne and Lombaerts, Tessa and Vanelderen, Pascal and Hubloue, Ives and Ordies, Sofie and Jan Van Asbroeck, Pieter (2026) Evaluating the impact of an on-site drug testing facility providing real-time drug alerts upon first-aid presentations at a Belgian festival. Drugs: Education Prevention and Policy, Early online. https://doi.org/10.1080/09687637.2026.2613864

17.

[News] RTE News. [RTE News] Rise in young people with ketamine-related bladder issues. (12 Jan 2026)

18.

[FactSheet] HRB National Drugs Library. (2026) Factsheet: New psychoactive substances (NPS) - the Irish situation 2026. Dublin: HRB National Drugs Library.

19.

[FactSheet] HRB National Drugs Library. (2026) Factsheet: Opioids - the Irish situation 2026. Dublin: HRB National Drugs Library.

20.

[FactSheet] HRB National Drugs Library. (2026) Factsheet: Sedatives and tranquilisers - the Irish situation 2026. Dublin: HRB National Drugs Library.

21.

[Article] Bastien, Gabriel and Abboud, Anita and McAnulty, Christina and Mahroug, Amani and Le Foll, Bernard and Socias, M Eugenia and Juteau, Louis-Christophe and Dubreucq, Simon and Jutras-Aswad, Didier (2026) Concordance between urine drug screening and self-reported use in the context of a pragmatic randomized-controlled trial in people with prescription-type opioid use disorder: Concordance entre le dépistage de drogues dans l'urine et l'usage autodéclaré dans le contexte d'un essai pragmatique contrôlé à répartition aléatoire chez des personnes présentant un trouble lié à l'usage d'opioïdes vendus sur ordonnance. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie, 71, (1), pp. 41-52. https://doi.org/10.1177/07067437251367180

22.

[Article] Canadian Centre on Substance Use and Addiction, Canada’s Drug Agency. (2026) Drug-checking technologies to detect compositions of unregulated substance samples. Canadian Journal of Health Technologies, 6, (1). https://doi.org/10.51731/cjht.2026.1328

23.

[Report] Public Health Scotland. (2026) Rapid Action Drug Alerts and Response (RADAR) quarterly reports 2026. Edinburgh: Public Health Scotland.

24.

[Article] Rock, Kirsten L and Treble, Ric and Copeland, Caroline S (2026) Legislating novel psychoactive substances: lessons from 15 years of UK mortality data (2007-2022). Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1708335

25.

[Article] Brennan, Margaret and Mongan, Deirdre and Doyle, Anne and Millar, Seán and Cavallaro, Massimo and Zgaga, Lina and Smyth, Bobby P and Nixon, Elizabeth and Ivers, Jo-Hanna and Galvin, Brian and Walsh, Cathal and McCrory, Cathal and McCarthy, Noel D (2026) Polysubstance use in early adulthood and associated factors in the Republic of Ireland: an analysis of a nationally representative cohort. Addiction, 121, (1), pp. 150-162. https://doi.org/10.1111/add.70182

26.

[Report] Medicines and Healthcare products Regulatory Agency. (2026) Drug safety update (DSU). Improving information supplied with gabapentinoids (pregabalin/gabapentin), benzodiazepines and z-drugs. London: Medicines and Healthcare products Regulatory Agency.

27.

[Article] Nielsen, Suzanne and Silva, João Pedro and Jones, Jermaine D and Krotulski, Alex and Poovendran, Dilkushi and Muzangizi, Deusdedit and Forte, Gilles and White, Jason and Comer, Sandra D (2026) Behavioural effects and naloxone effectiveness with new synthetic opioids. Drug and Alcohol Review, 45, (1). https://doi.org/10.1111/dar.70040

28.

[Article] Paredes Naveda, Alisson M and Oliva, Henrique Nunes Pereira and Ghadimi, Delaram J and Angarita, Gustavo A (2026) Actigraphy-based sleep outcomes in substance use disorders: a protocol for a systematic review and meta-analysis. PLoS ONE, 21, (1). https://doi.org/10.1371/journal.pone.0340595

29.

[Article] Poulter, Hannah Louise and Silva, Peter Da and Moore, Helen J and Kesten, Joanna and MacKinnon, Mandy and Taylor, Gillian (2026) Peer research with populations of people who use street tablets in areas over-represented by drug-related harms in the UK: a case study. Harm Reduction Journal, 23. https://doi.org/10.1186/s12954-025-01273-1

30.

[Article] Radcliffe, Polly and Smith, Emma and Lewis, Shirley and Honeybul, Louise and Gilmour, Lynne and Maxwell, Margaret and Neale, Joanne and Featherstone, Brid and Gonzalez Utrilla, Mariana and Aladangady, Narendra and Cheyne, Helen (2026) Navigating surveillance: the experience of prenatal women who use or who are in treatment for using drugs. The British Journal of Social Work, 56, (1), pp. 86-105. https://doi.org/10.1093/bjsw/bcaf161

31.

[Article] Roberts, Emmert and Hillyard, Miriam and Copeland, Caroline (2026) Characteristics of drug-related deaths among individuals identified as LGBTQ+ in the United Kingdom, 1997-2024. Addiction, 121, (1), pp. 208-214. https://doi.org/10.1111/add.70198

32.

[Article] Roberts, Emmert and McKetin, Rebecca and Copeland, Caroline (2026) Characteristics of methamphetamine-related deaths in the United Kingdom, 1997-2024. Addiction, 121, (3), pp. 680-685. https://doi.org/10.1111/add.70215

33.

[Article] Siefried, Krista J and Smith, Janette L and Harvey, Christine A and Nedanoski, Anthony and Brown, Jared A and Cullinan, Una and Ezard, Nadine and Jiranantakan, Thanjira and Roberts, Darren M and Brett, Jonathan (2026) Emergency department presentations, hospitalisations and police seizure data related to gamma-hydroxybutyrate (GHB) in New South Wales, Australia, from 2015 to 2024. Addiction, 121, (2), pp. 305-315. https://doi.org/10.1111/add.70202

34.

[Article] Sommer, Michaela J and Grafinger, Katharina Elisabeth and Hermanns-Clausen, Maren and Auwärter, Volker (2025) Development of a novel risk score reflecting the relative harm potential of synthetic cannabinoids based on prevalence estimates, well-documented intoxication cases and basic pharmacological data. Addiction, Early online. https://doi.org/10.1111/add.70268

35.

[Report] Forensic Science Ireland. (2025) Forensic Science Ireland annual report 2024. Dublin: Forensic Science Ireland.

36.

[Report] An Garda Siochana. (2025) An Garda Síochána annual report 2024. Dublin: An Garda Siochana.

37.

[Report] Medical Bureau of Road Safety. (2025) Medical Bureau of Road Safety annual report 2024. Dublin: Medical Bureau of Road Safety.

38.

[Article] Shiwach, Rajinder and Le Foll, Bernard and Alho, Hannu and Dunn, Kelly E and Strafford, Stephanie and Zhao, Yue and Dobbins, Robert L (2025) Comparison of extended-release buprenorphine doses for treating high-risk opioid use: a randomized clinical trial. JAMA Network Open, 8, (12). 10.1001/jamanetworkopen.2025.48043

39.

[Report] Kelleher, Cathy and Riordan, Fiona and Gopalakrishnan, Arya (2025) Drug poisoning deaths in Ireland in 2022: data from the National Drug-Related Deaths Index (NDRDI). Dublin: Health Research Board.

40.

[Report] Advisory Council on the Misuse of Drugs. (2025) Advisory Council on the Misuse of Drugs annual report (January 2023 to December 2025 consolidated). London: Advisory Council on the Misuse of Drugs.